“Also it makes for an excellent tool for media opportunities if a producer or editor is on a fence about covering the company.”

The approval of the open label extension isn’t likely to sway the media. The media, at this point in the pandemic, wants to discuss results and is past the hype of potential therapeutics. NP and CYDY have media lined up to talk about the release of data and have media lined up if/when the S/C trial is successful.